Warp Science, a startup founded by former OpenAI executive Kevin Weil, has secured $215 million at an $865 million valuation. The company aims to automate wet-lab chemistry for drug discovery, potentially challenging traditional contract manufacturing models by moving research facilities closer to home.
Warp Science, a newly launched artificial intelligence startup, has raised $215 million in a funding round that values the company at $865 million. The business is founded by Kevin Weil, a former executive at OpenAI, and focuses on applying AI to automate the physical work done in biological laboratories.
The core objective of the company is to transform how drugs are discovered by replacing human-intensive, slow wet-lab processes with high-speed robotics. By training mechanical systems to synthesize and test molecular variations through sensor-based learning, the firm aims to drastically speed up the drug development cycle. In this model, chemists use sensor-equipped tools to teach robots how to perform complex laboratory tasks, allowing the machines to operate in continuous 24-hour cycles.
Impact on Outsourced Manufacturing
The move towards domestic, automated laboratories signals a potential shift in the global biotechnology supply chain. For years, the industry has relied heavily on third-party contract research and manufacturing organizations, such as WuXi AppTec, to handle the labor-intensive synthesis of molecules. Warp Science seeks to bring these capabilities back onshore, reducing the reliance on international logistics and shielding drug discovery pipelines from the risks of geopolitical instability or supply chain disruptions.
While the concept aims to improve speed and security, it introduces new challenges. Investors will be tracking whether this automated, domestic model can compete with the cost structures of established global manufacturing hubs. Scaling physical infrastructure—often referred to as hardware-heavy research—carries significant execution risks. Unlike software-only AI businesses, this model requires constant maintenance of robotics, investment in physical space, and the ability to prove that automated results meet strict scientific standards required for drug approval.
Backing and Future Milestones
The funding round attracted prominent venture capital firms including Lightspeed, IVP, Premji Invest, and Lux Capital. This capital is earmarked for scaling the company's robot fleet and building the necessary infrastructure to bridge the gap between AI-identified molecular compounds and physical prototype testing. For the biotechnology sector, the success of this venture will depend on its ability to prove that automated labs can consistently outpace the efficiency of traditional, manual research methods while remaining commercially viable. Investors will likely watch the company’s ability to scale these facilities and secure partnerships with major pharmaceutical developers to validate their technology.